The PARP inhibitor market was valued at USD 6.8 billion in 2025, is projected to reach USD 17.0 billion by 2036 and is forecast to register an 8.7% CAGR between 2026 and 2036. In 2026, olaparib holds 86.2% of drug type sales and ovarian cancer represents 83.9% within the indication segment.